Who are Alpha-1 antitrypsin (AAT)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alpha 1-Antitrypsin, Aralast NP, Alpha1-Proteinase Inhibitor, alpha-1-Proteinase Inhibitor, NRL972.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha-1-antitrypsin-aat.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Alpha-1 antitrypsin (AAT) — Competitive Intelligence Brief

Alpha-1 antitrypsin (AAT) (Alpha-1 antitrypsin (AAT)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor / Protein replacement therapy. Area: Pulmonology / Genetic / Rare Disease.

phase 3 Protease inhibitor / Protein replacement therapy Neutrophil elastase Pulmonology / Genetic / Rare Disease Biologic Live · refreshed every 30 min

Target snapshot

Alpha-1 antitrypsin (AAT) (Alpha-1 antitrypsin (AAT)) — CSL Behring. Alpha-1 antitrypsin (AAT) is a protease inhibitor that replaces deficient endogenous AAT to prevent neutrophil elastase-mediated tissue destruction in the lungs and other organs.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Alpha-1 antitrypsin (AAT) TARGET	Alpha-1 antitrypsin (AAT)	CSL Behring	phase 3	Protease inhibitor / Protein replacement therapy	Neutrophil elastase
Alpha 1-Antitrypsin	Alpha 1-Antitrypsin	University of Minnesota	marketed	Protease inhibitor; protein replacement therapy	Neutrophil elastase
Aralast NP	Aralast NP	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Protease inhibitor (augmentation therapy)	Alpha-1 protease inhibitor (AAT); neutrophil elastase inhibition
Alpha1-Proteinase Inhibitor	Alpha1-Proteinase Inhibitor	Baxalta now part of Shire	marketed	Protease inhibitor (protein replacement therapy)	Neutrophil elastase (indirect target via AAT inhibition)
alpha-1-Proteinase Inhibitor	alpha-1-Proteinase Inhibitor	Institute for Human Genetics and Biochemistry	marketed	Protease inhibitor / Enzyme replacement therapy	Neutrophil elastase
NRL972	NRL972	Norgine	phase 3	Neutrophil elastase inhibitor	Neutrophil elastase (NE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor / Protein replacement therapy class)

CSL Behring · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alpha-1 antitrypsin (AAT) — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha-1-antitrypsin-aat. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab